Stockreport

Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial [Yahoo! Finance]

Cell Source, Inc.  (CLCS) 
PDF NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source", or the "Company"), a pioneer in Veto Cell-based immunotherapy, today shar [Read more]